Humanized Syngeneic Models

Humanized mouse models enable rapid testing of human target-specific immunotherapy drug candidates by providing genetically engineered human targets in a fully immunocompetent host.

Our humanized mouse models can help you understand your drug’s mechanisms of action, kinetics, toxicity profile, and potency, allowing you to select a drug candidate with the highest chance of success in the clinic.

Our team of experts have extensive knowledge in the field of preclinical modelling and long-standing expertise in assessing the efficacy and potency of immuno-oncology drug candidates using humanized mouse models.

What we offer:

A panel of well-established models expressing clinically-relevant human targets (developed in collaboration with genOway)
Models suitable for response to human immune checkpoint inhibitors (e.g. Pembrolizumab, Nivolumab, Ipilimumab) to evaluate combinations strategies with your test compound
Flow cytometry readout for immune cell profiling
A team of expert immunologist available to guide your study design and support data analysis

Reach out today to discuss how we can fast-track your immunotherapy research.

Contact an expert

Meet us at your next conference

Humanized Syngeneic Mouse Models Available at Reaction Biology

Humanized hPD-1 Model

Setup:
The humanized hPD-1 mouse has been developed in the mouse C57BL/6N background. To this mouse strain’s PD-1 locus, a chimeric PD-1 with a human extracellular domain, a murine transmembrane domain, and an intracellular domain has been inserted (C57BL/6N-^{Pdcd1tm1.1((PDCD1)Geno)}), allowing human-specific therapeutic Abs to interact with the human domain of this chimeric PD-1 protein, while the murine intracellular domain facilitates all murine specific downstream events.

Goal:
For in vivo efficacy and potency assessment and profiling of human immune checkpoint hPD-1 targeting immunotherapeutic agents in a fully immune-competent humanized mouse model.

Tumor cell line:
MC38-CEA, expressing human CEA, was engrafted subQperior™ in the hPD-1 expressing C57BL/6N model, to test the efficacy of human specific immunotherapeutic agent Pembrolizumab targeting human immune checkpoint hPD-1. As a control murine-specific anti-PD-1 Abs (RPM1-14) was used to allow for monitoring of human-specific anti-tumor response.

Results: